Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has been awarded Current Good Manufacturing Practice (cGMP) authorization by the Saudi Food and Drug Authority (SFDA).
Julphar Saudi Arabia, a joint venture in between Julphar and its local partner Cigalah Group, is the very first pharmaceutical company in King Abdullah Economic City (KAEC) to gain full cGMP certification on its first inspection.
Commenting on the announcement, Sheikh Abdullah Bin Faisal Al Qasimi, Chairman of Julphar Saudi Arabia, claimed: "Congratulations to everybody who made this crucial qualification feasible. Saudi Arabia is our biggest market and we continuously see a strong opportunity for growth in the country.
" This certificate will certainly add value to our company, reinforce our commitment to the health industry of Saudi Arabia and add to Julphar's 2020 vision of increasing our manufacturing presence in the region."
The SAR 300 million state-of- the-art manufacturing facility was officially inaugurated in April 2017 by Dr Tawfiq Al Rabiah the Minister of Health Kingdom of Saudi Arabia. The factory has the capability to produce 1 billion tablets, 300 million capsules and 30 million containers of syrups and suspensions each year.
Ibrahim Al Makhadi, General Manager of Julphar Saudi Arabia, said: " We are thrilled to receive cGMP approval, an accomplishment that paves the way for a strong business existence in the country according to the 2030 vision of the Kingdom of Saudi Arabia.
" I would like to take this chance to congratulate and say thanks to all my Julphar Saudi team, that have faithfully, eagerly, and assiduously shed midnight oil to make this accomplishment. I would certainly additionally want to thank all the participants of Julphar Ras Al Khaimah who sustained us in accomplishing this objective."
Julphar, one of the largest pharmaceutical makers in the Middle East and Africa, was established in 1980 under the advice of His Highness Sheikh Saqr Bin Mohammed Al Qasimi. The company uses 5,000 people and distributes a wide range of products to more than 50 nations on 5 continents around the world.
Julphar's business is centered on three core systems - Diabetes Solutions, General Medicines, and its consumer division, Julphar Life. The company’s product portfolio of tablets, liquids, creams andminjectables target major therapeutic segments including Family Care, Gastrology, Pain and Wound Management, Antibiotic, Cardiovascular and Metabolism.
For more information, browse through http://www.julphar.net